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Abstract: The present investigation was conducted to examine the relationship 
between immunological parameters and prognosis in cases of invasive bladder cancer. A 
total of 48 patients were entered into this study. They underwent invasive treatment which 
may greatly affect host immunity(e. g. radical surgery， radiation therapy and cisplatin 
based combination chemotherapy). Immunological parameters include peripheral 
lymphocyte count， IgG， IgA， IgM， C3， C4， IgG-FcR(十)Tcel， OKT4/8 ratio and Su-PS skin 
test; these were examined before and 1， 3 and 6 months after treatment. Peripheral 
lymphocyte count in the BRM untreated group showed a significant difference between 
before and after chemotherapy or surgery. Su-PS skin reaction in the BRM untreated 
group also showed a significant difference between before and after surgery. There were 
significant differences in OKT 4/8 ratios between cancer death group and no evidence of 
disease group. These results suggest that OKT4/8 ratio may reflect the prognosis of 
patients with invasive bladder cancer. In addition， lymphocyte count and Su-PS skin 
reaction may be parameters of indication for BRM treatment. 
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対象は，奈良医大泌尿器科で 1982年 4月より 1991年
5月の聞に治療した浸潤性勝脱癌 48例で，内訳は男性
41 例，女性 7 例，平均年齢 63.1(38~82)歳である (Table
治療前臨床病期を跨脱癌取扱い規約に準じて分類する
と， T分類では Tis4例， Tl(G3) 5例， T2 5例.T325
例， T4 9例で， N分類では NO37例， N1 3例， N2 7 
例， N3 0例， N4 1例で， M分類では MO45例， M1 3 
例で，発育様式による分類では乳頭状腫療が 5例，非乳
頭状腫療が 43例あった.また，生検による病理組織診断










IgG， IgA， IgM， C3， C4， PHA幼若化反応， IgG-FcR( +) 
T細胞， OKT4/8比， Su-PS皮内反応を用い， Su-PS皮
内反応は長径と短径の平均を測定値とした.これらのパ











Table 1. Patient characteristics 





























* Those cases with superficial bladder cancer were 
tr田 ted with chemoradiotherapy and operation 
according to N ara Urooncological R巴searchGroup 
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Fig. 4. Changes of OKT 4/8 ratios of cases in no 




































Fig. 5. Survival rates according to OKT 4/8 ratio. 
(123) 
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Fig. 6. Comparison of OKT 4/8 ratios b巴tween
locally invasive bladder cancer group (T孟
3NOMO) versus advanced bladder cancer 
























かし，藤原町土，跨脱癌症例 50例における IgG-FcR(+) 
T細胞について検討したところ，浸潤性勝脱癌症例群
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